#### STEM CELLS AS THE MAIN STRATAGEM OF BIOLOGICAL REGENERATIVE MEDICINE:

#### FROM ANTI-AGING AND PREVENTIVE MEDICINE TO TREATMENT OF CHRONIC DEGENERATIVE DISEASES

**Dr. Dmytro Klokol** European Wellness Centers International European Wellness Academy (Germany, APAC)

www.European-wellness.com Dr.dmytro@european-wellness.com

# // pugnandum, tamquam contra

morbum sic contra senectutem //

"we have to fight against aging, as we do against a disease"

Cicero

In principle, if you understood the mechanisms of keeping things repaired, you could keep things going indefinitely *J* 

Cynthia Kenyon

#### MAMMALIAN AGING CAN BE DELAYED WITH

Genetic

Dietary

Pharmacological

Biological & biotechnological

#### WORLD POPULATION AGEING 2015.



United Nations, Department of Economic and Social Affairs, Population Division.



Karsdal et al. Am J Physiol, 2015





Kennedy, Berger, Brunet and Tony Wyss-Coray "Aging: a common driver of chronic diseases and a target for novel interventions", Cell, 2016.

- Metformin
- Quercetin
- Resveratrol
- Dasatinib
  - etc...

Tumor suppressor p53

•

SIRT<sub>1-3</sub> genes

• IGF-1

- Toll-like receptor family
- mTOR

Death takes place because a worn-out tissue cannot forever renew itself, and because

a capacity for increase by means of cell division is not everlasting but finite.



Kasdal et al. Am J Physiol, 2015

### FRESH CELL THERAPY STUDY

- Risks and benefits assessment and statistical evaluation
- Done by Independent Consultants in Medical Statistics and Biometry in Medicine
- Main investigator DR. Volker W. Rahlfs, CStat (RSS/UK), Biometry in Medicine (GMDS)
- 186 patients from 22 countries
- Allergic reactions in a mild form 1.07%
- Clinical improvement 98.4%
- Desire to repeat therapy 97.8%

#### BENEFICIAL

#### DETRIMENTAL

- Embryonic development
- Tissue regeneration
- Wound healing
- Tumor suppression (p53 inact)



- Tissue degeneration
- Chronic inflammation
- Tumor promotion (p53 deficient)

#### AGEING

#### **MITOCHONDRIAL FUNCTION AND ANTI-OXIDANT SYSTEM ASSAY**

- Serum Humanin and SHLP 1-6 levels measured with standard Commercial Humanin enzyme-linked immunosorbent assay (ELISA) Kit
- Superoxyde dismutase (SOD2) assay Commercial SOD ELISA kit
- Catalase assay Aebi method (1984) in modification of Mittal and Flora, 2007
- Reduced and Total serum Glutathione measured with Glatathione Assay Kit (Sigma-Aldrich)

#### **MITOCHONDRIAL FUNCTION ASSAY**



#### **ANTI-OXIDANT SYSTEM ASSAY**

6 5 4 3 2 1 Normal value μmol/L Prior to treatment μmol/L After the treatment μmol/L

**Reduced Glutathione assay** 

SOD2 and catalase assay



Mean RGx increase from 2.9±0.03 to 4.3±0.04 µmol/L

#### **PROOF OF ANTI-AGING PROPERTIES AND BIOLOGICAL ACTIVITY**

Biological clock shift (DNAm age test)



#### 4-9 years rejuvenating effect, Mean rejuvenation by 6-8 years

M. Chan and D. Klokol. Stem cells in regenerative medicine, 2019.

## **MSCs**









Neuron

Courtesy of www.fetal-cells.com

NucBlue stain 10x 2x magnification Characteristics: Suspension





Courtesy of www.fetal-cells.com

NucBlue stain 10x 2x magnification Characteristics: Suspension





Courtesy of www.fetal-cells.com

NucBlue stain 10x 1.6x magnification Characteristics: Adherent, elongated

## Pancreas



Courtesy of www.fetal-cells.com

Mitotracker stain 10x 1.6x magnification Characteristics: Adherent, elongated

### 2. MICROSCOPIC IDENTIFICATION – FLUORESCENCE MICROSCOPY (SPECIFIC MARKERS)



Bright Field microscopy (10x)

Fluorescence microscopy (10x)

Microscopy images of xenogeneic (rabbit) mesenchymal cells immunostained with CD44 surface markers. (AbD Serotec, Inc., Raleigh, NC, USA) (Bakhtina et al., 2013)

## 2. MICROSCOPIC IDENTIFICATION – FLUORESCENCE MICROSCOPY (SPECIFIC MARKERS)



Neural stem cells: Cy3-NSE and Cy3-GFAP immunofluorescent staining

(Shen et al., 2010)



# STAGE 3 Significant liver damage

STAGE 4 Severe liver damage (Cirrhosis)

PROGRESSION OF LIVER DAMAGE			
HEALTHY LIVER	FIBROTIC LIVER	CIRRHOTIC LIVER	LIVER CANCER
		A States	
		Mar .	ARE
	1 States	Contraction of the second	

### FATTY LIVER DISEASE AND LIVER FAILURE

### **CELL THERAPY IN LIVER DISEASE**

- Implanted cells begin to secret albumin within first 48 hrs post implantation
- Various routes of implantation available
- Applicable in either acute or chronic liver failure as well as metabolic syndrome (Crigler-Najaar, Gilbert syndrome, etc)
- Results in improvement of liver function test, reduction of ammonia, reduction of encephalopathy, and cardiovascular instability

Journal of Scientific Research and Studies Vol. 3(6), pp. 119-125, June, 2016 ISSN 2375-8791 Copyright © 2016 Author(s) retain the copyright of this article http://www.modernrespub.org/jsrs/index.htm



Full Length Research Paper

### Efficacy of renal precursor stem cells in management of chronic kidney disease: a cohort study

Mike Chan<sup>1</sup>, Michelle Wong<sup>2</sup>, Mikhail Teppone<sup>1</sup>, Dina Tukhvatullina<sup>1</sup> and Dmitry Klokol<sup>1</sup>\*

<sup>1</sup>Stellar Biomolecular Research, Germany. <sup>2</sup>Frontier Cytobiological Therapies International, EU.

\*Corresponding author. E-mail: Dr.dmytro@sbi-europe.com

Accepted 24 June, 2016

In spite of tremendous achievements of modern medical science, chronic kidney disease (CKD) is still

www.European-wellness.com

#### **OBTAINED RESULTS**



CKD stage 3a – down-staging of CKD in 78.5% CKD stage 3b – down-staging of CKD in 66.7%

#### **PSC IN CARDIOMYOPATHY**





age

**CARDIAC CELL TURNOVER** 

Bergmann O., 2009, Cell

acti



Forward Scatter

Van den Akker, 2016

#### **CELL THERAPY IN CARDIOMYOPATHY**

- Effect observed after 3 months or more and may last up to 2 years
- EF increase from 13.5% to 20% depending on the case
- Downstaging of NYHA FC observed in practically all cases within 6 months of treatment
- Re-implantation of PSC within 3-6 months significantly improves long-term outcomes
- Prolonged administration of cardiac-specific peptides and growth factors is pivotal for successful treatment



This study provides evidence that neural stem cells can safely survive in brain and have the potential to be used as a replacement therapy after a neurological injury such as a brain stroke. It has been demonstrated that undifferentiated fetal cells can support a functional recovery from parkinsonian symptoms, survive and migrate to lesioned brain areas for up to 7 months. They differentiate into dopaminergic neural fibers in close association with host neurons and express the glial cell line-derived neurotrophic cell factor (GDNF), that may provide protective support to dopaminergic neurons.



- Initial data have shown improvement in 30% of the patients with Parkinson or Huntington disease after xenotransplantation with fetal neuronal cells (*Fink JS, Schumacher JM et al*).
- 14 weeks after transplantation of fetal neural progenitor cells transplants, only mild infiltration of CD8 T cells and macrophages was noticed
- Improved prescriptions allowed increase efficacy to 70-75% in Alzheimer's and Parkinson's
- Ongoing Xenome project UE LSHB-CT-2006-037377 currently continues evaluation of fetal precursor stem cell application efficacy in Parkinson's disease.



69 y.o. patient with 15 years history of Parkinson's treated with xenogeneic stem cells, demonstrated dramatic recovery but passed away due to a different cause (acute pulmonary embolism).

#### Cresyl violet stain for xenogeneic CD44 antigen

Tyrosine hydroxylase – dopamine cell marker

NF70 xenogeneic neurofilament axon marker

From Deacon et al. Natur med, 1997

### **ALZHEIMER'S DISEASE AND DEMENTIA**

Name: DBR (Male)

Age: 82 years old as of 04/11/2009

Symptoms: Insomnia, lethargy, memory loss, slow and slur speech, quick temper,

lost muscle strength and libido, chronic fatigue and disorientation.

#### Attending physician's comments:

- More energetic as he is able to walk longer distance and faster than before without complication
- Less frequent after lunch nap
- More enthusiastic e.g in gardening, activities at home, qigong workshop
- Great improvement in mood
- Ability in thinking and planning ahead, improvement in heart ejection fraction.

#### Wife's feedback:

- Infrequent mood swings, emotionally stable.
- Blood pressure and cholesterol normal range.
- Speech expressivity is good.
- ECG good, Rhythm good.
- Cardiologist commented that he is doing well and will only see him after 12 months.

#### **Patient's Feedback:**

- Better memory.
- Better mobility, can walk further than before, can do mild exercises without resting and has more energy.
- Short of breath if he's rushing, anxious & worried.
  Sleep apnea has improved.



Photo dated September 2013 – Buddhist temple in China Courtesy of www.fetal-cells.com



Photo dated October 2013



New lease: Erk Brown is enjoying working in the garden after stemcell treatment in Kuala Lampac, Prove stepped on a

processing an Island and de to be refugee tralian court challenge. Lawyers & sockers facis challenge the





epner, 3919,6(3), 66-78

#### EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

SJEF Impact Factor 4.897 Review Article 198N 2394-3211

www.elnim.com

EIPME

#### MELATONIN, PINEAL GLAND AND SLEEP DISORDERS: FROM THEORY TO PRACTICE

#### Dins Tulins", Patricis Pan and Dmitry Klekol

European Wellness International Group (EU, APAC), Stellar Biomolecular Research (Germany).

\*Corresponding Aethor: Dine Tulma

European Wellasen International Group (EU, APAC), Stellar Biomolecular Research (Germany)

Article Received on 30/15/2018

Article Revised on 2840 2019

Article Accepted on 1140/2019

#### ABSTRACT

The article discusses the physiology of sleep and mechanisms of sleep disorders. Possible therapeutic solutions to treat sleep disorders can be provided through functional and holistic biological medicine, which employs a number of device-based treatments, stem cells and therapy with paseal gland cell extracts.

KEYWORDS: Pineal gland, sleep, sleep disorders, incomma, stem cells.

The conundrum of sleep has always drawn special suffer from some form of sleep desorder.<sup>11-11</sup> In some attention not only as a biological process but also due to severe cases, which are relatively uncommon, substantial

#### www.European-wellness.com

### **HOW TO SUCCEED**

- Profound analysis of patient's state of health: screening of biological markers of aging i.e.
  complete hormonal profiling including precursor of hormones DHEA, ferritin, IGF, epigenetic test, parameters of the oxidative stress, mitochondrial function etc
- Don't neglect "minor things", as there are no "minor things".
- 3. More trials, research and experience.

www.European-wellness.com

#### THANK YOU FOR YOUR KIND ATTENTION

Dr.dmytro@european-wellness.com www.European-wellness.com